Factors Affecting the Pharmacology of Antibody–Drug Conjugates

@inproceedings{Lucas2018FactorsAT,
  title={Factors Affecting the Pharmacology of Antibody–Drug Conjugates},
  author={Andrew Thomas Lucas and Lauren S. L. Price and Allison N. Schorzman and Mallory Storrie and Joseph A. Piscitelli and Juan Razo and William C. Zamboni},
  year={2018}
}
Major advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have created revolutionary drug delivery systems in cancer over the past decade. While these immunoconjugate agents provide several advantages compared to their small-molecule counterparts, their clinical use is still in its infancy. The considerations in their development and clinical use are complex, and consist of multiple components and variables that can affect the pharmacologic characteristics. It is… CONTINUE READING

Figures and Tables from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 182 REFERENCES

Antibody-drug conjugates—an emerging class of cancer treatment

  • British Journal of Cancer
  • 2016
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Biologics: an update and challenge of their pharmacokinetics.

  • Current drug metabolism
  • 2014
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL